Cargando…
The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data
Literature regarding the effect of biologics on the course of mycosis fungoides (MF) is scarce. This multicentre study analysed retrospective data on 19 patients with MF, who were treated with biologics; 12 for inflammatory conditions coexisting with MF, and 7 for MF misdiagnosed as an inflammatory...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Publication of Acta Dermato-Venereologica
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234989/ https://www.ncbi.nlm.nih.gov/pubmed/32965506 http://dx.doi.org/10.2340/00015555-3642 |
_version_ | 1784736208164749312 |
---|---|
author | AMITAY-LAISH, Iris GUENOVA, Emmanuella ORTIZ-ROMERO, Pablo L. VICO-ALONSO, Cristina ROZATI, Sima GESKIN, Larisa J. NIKOLAOU, Vasiliki PAPADAVID, Evangelia BARZILAI, Aviv PAVLOVSKY, Lev DIDKOVSKY, Elena NAVEH, Hadas PRAG AKILOV, Oleg E. HODAK, Emmilia |
author_facet | AMITAY-LAISH, Iris GUENOVA, Emmanuella ORTIZ-ROMERO, Pablo L. VICO-ALONSO, Cristina ROZATI, Sima GESKIN, Larisa J. NIKOLAOU, Vasiliki PAPADAVID, Evangelia BARZILAI, Aviv PAVLOVSKY, Lev DIDKOVSKY, Elena NAVEH, Hadas PRAG AKILOV, Oleg E. HODAK, Emmilia |
author_sort | AMITAY-LAISH, Iris |
collection | PubMed |
description | Literature regarding the effect of biologics on the course of mycosis fungoides (MF) is scarce. This multicentre study analysed retrospective data on 19 patients with MF, who were treated with biologics; 12 for inflammatory conditions coexisting with MF, and 7 for MF misdiagnosed as an inflammatory skin disease. Eight patients were treated with anti-tumour necrosis factor-α-monotherapy; 6 had early-stage MF, in 3 patients MF preceded and in 3 MF was diagnosed after initiation of biologics, with no stage-progression or with stable disease, respectively (median treatment time concurrent with MF 57 months). Two patients had advanced stage MF: IIB, treated for 15 months with no stage-progression, and IVA1, treated for 8 months, died of disease 10 months later. The other 11/19 patients received anti-interleukin-17A and/or antiinterleukin-12/23 or anti-interleukin-23 (with/without anti-tumour necrosis factor-α/anti-interleukin-4/13), with stageprogression in 8 patients after a median of 8 months’ treatment. Although, in general, biologics should be avoided in patients with MF, these results indicate that anti-tumour necrosis factor-α-monotherapy might not aggravate the disease course in early-stage patients. Interleukin-17A, interleukin-12/23 and interleukin-23 pathway-blockers may prompt progression of MF. |
format | Online Article Text |
id | pubmed-9234989 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Society for Publication of Acta Dermato-Venereologica |
record_format | MEDLINE/PubMed |
spelling | pubmed-92349892022-10-20 The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data AMITAY-LAISH, Iris GUENOVA, Emmanuella ORTIZ-ROMERO, Pablo L. VICO-ALONSO, Cristina ROZATI, Sima GESKIN, Larisa J. NIKOLAOU, Vasiliki PAPADAVID, Evangelia BARZILAI, Aviv PAVLOVSKY, Lev DIDKOVSKY, Elena NAVEH, Hadas PRAG AKILOV, Oleg E. HODAK, Emmilia Acta Derm Venereol Clinical Report Literature regarding the effect of biologics on the course of mycosis fungoides (MF) is scarce. This multicentre study analysed retrospective data on 19 patients with MF, who were treated with biologics; 12 for inflammatory conditions coexisting with MF, and 7 for MF misdiagnosed as an inflammatory skin disease. Eight patients were treated with anti-tumour necrosis factor-α-monotherapy; 6 had early-stage MF, in 3 patients MF preceded and in 3 MF was diagnosed after initiation of biologics, with no stage-progression or with stable disease, respectively (median treatment time concurrent with MF 57 months). Two patients had advanced stage MF: IIB, treated for 15 months with no stage-progression, and IVA1, treated for 8 months, died of disease 10 months later. The other 11/19 patients received anti-interleukin-17A and/or antiinterleukin-12/23 or anti-interleukin-23 (with/without anti-tumour necrosis factor-α/anti-interleukin-4/13), with stageprogression in 8 patients after a median of 8 months’ treatment. Although, in general, biologics should be avoided in patients with MF, these results indicate that anti-tumour necrosis factor-α-monotherapy might not aggravate the disease course in early-stage patients. Interleukin-17A, interleukin-12/23 and interleukin-23 pathway-blockers may prompt progression of MF. Society for Publication of Acta Dermato-Venereologica 2020-09-30 /pmc/articles/PMC9234989/ /pubmed/32965506 http://dx.doi.org/10.2340/00015555-3642 Text en © 2020 Acta Dermato-Venereologica https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the CC BY-NC license |
spellingShingle | Clinical Report AMITAY-LAISH, Iris GUENOVA, Emmanuella ORTIZ-ROMERO, Pablo L. VICO-ALONSO, Cristina ROZATI, Sima GESKIN, Larisa J. NIKOLAOU, Vasiliki PAPADAVID, Evangelia BARZILAI, Aviv PAVLOVSKY, Lev DIDKOVSKY, Elena NAVEH, Hadas PRAG AKILOV, Oleg E. HODAK, Emmilia The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data |
title | The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data |
title_full | The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data |
title_fullStr | The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data |
title_full_unstemmed | The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data |
title_short | The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data |
title_sort | course of mycosis fungoides under cytokine pathway blockers: a multicentre analysis of real-life clinical data |
topic | Clinical Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234989/ https://www.ncbi.nlm.nih.gov/pubmed/32965506 http://dx.doi.org/10.2340/00015555-3642 |
work_keys_str_mv | AT amitaylaishiris thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT guenovaemmanuella thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT ortizromeropablol thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT vicoalonsocristina thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT rozatisima thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT geskinlarisaj thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT nikolaouvasiliki thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT papadavidevangelia thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT barzilaiaviv thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT pavlovskylev thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT didkovskyelena thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT navehhadasprag thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT akilovolege thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT hodakemmilia thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT amitaylaishiris courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT guenovaemmanuella courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT ortizromeropablol courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT vicoalonsocristina courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT rozatisima courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT geskinlarisaj courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT nikolaouvasiliki courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT papadavidevangelia courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT barzilaiaviv courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT pavlovskylev courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT didkovskyelena courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT navehhadasprag courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT akilovolege courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata AT hodakemmilia courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata |